First Eagle Overseas Equity ETF (FEOE)
Live price chart, market sentiment, and community perspectives for First Eagle Overseas Equity ETF (NYSE: FEOE).
Live price chart, market sentiment, and community perspectives for First Eagle Overseas Equity ETF (NYSE: FEOE).
On our desk, FEOE has captured attention due to its striking short-term outperformance in the Foreign Large Blend category, logging a 31.76% 1-year return compared to the category's 26.63% as of mid-2026. The fund's active share sits near 89.8%, and its price/earnings ratio of 16.11 gives it a distinct value-oriented positioning. However, looking at market sentiment, traders are cautious about reading too much into these figures given the ETF's inception date in December 2024 (or late 2023 filings). The valuation discipline reflects classic Graham and Buffett principles—searching for a 'margin of safety' in out-of-favor industries—but sentiment demands a longer track record before declaring structural superiority.
Reviewing the risk disclosures and profile data, FEOE presents a mixed risk picture. Its 1-year beta of 0.58 indicates significantly lower market sensitivity than the broader category, likely bolstered by First Eagle's historical deployment of cash and gold-related macro buffers. Yet, Morningstar's low 3-year and 5-year return-vs-category markers remind us that lower volatility doesn't automatically equate to optimal risk-adjusted peer standing across various market cycles. Furthermore, being an unhedged fund in foreign equities, it remains entirely vulnerable to USD currency strength events—similar to the headwinds seen in 2022—and lacks concrete benchmark drawdown statistics specific to its short lifespan.
From a quantitative and operational protocol standpoint, evaluating FEOE requires keeping a close eye on its structural execution. With 76 holdings, a weighted average market cap of $142.34 billion, and a very low portfolio turnover of 10% (compared to a category average of 38%), the fund demonstrates a patient, low-turnover approach that helps control transaction costs and tax-cost ratios (sitting around 0.6%). When underwriting or discussing this asset with clients, analysts must emphasize that its historical outperformance—like the 4.6% monthly return in July 2026—is tied closely to an active management style that actively seeks out companies with temporary operational distress or cyclical market overshoots.
Explore plasma cleansing, somatic organ swaps, and BCI.